Atul Gawande (Photo: Amar Karodkar/Wikimedia Commons CC-4.0)
Everything about Amazon.com Inc., Berkshire Hathaway Inc., and J.P. Morgan Chase & Co.'s enigmatic effort to reduce health care costs has been unusual.
On Wednesday, the triumverate stuck to their strange guns by picking renowned surgeon, writer and Harvard public-health researcher Atul Gawande to run their new company.
It's easy to peg the choice as something of a victory for incumbents. Gawande is brilliant. But he has no experience in managing a large organization, or in the practical aspects of managing employee health care costs. He'll face a steep learning curve. And it's still unclear what this organization will actually do beyond producing buzzword-laden press releases.
But it's hard to imagine a more fascinating person to empower with the combined resources of companies worth $1.6 trillion and a long leash. Tangible results may take longer than they would if an industry insider were to take charge, or if the venture were to narrowly focus on something like drug costs. But they are likely to be much more interesting.
Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and
